Growing Cardiovascular Disease Cases Fueling The Growth Of The Market Due To Rising Need For Early Diagnosis And Monitoring Emerges as a Core Driver of the Blood Based Biomarkers Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Blood Based Biomarkers Market Through 2025?
The market size for blood-based biomarkers has seen swift growth in the previous years. The market, which stands at $23.13 billion in 2024, is projected to increase to $25.83 billion by 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 11.6%. The upward trend during the historic period is due to factors such as the escalating global prevalence of cancer, the rise in the adoption of personalized treatment approaches, amplified investment in biomarker research, an increase in clinical trials involving biomarkers, and an upswing in companion diagnostics approvals.

What's the Projected Size of the Global Blood Based Biomarkers Market by 2029?
Rapid expansion is anticipated in the blood-based biomarkers market within the coming years, projecting a growth to "$40.66 billion in 2029 with a compound annual growth rate (CAGR) of 12.0%. The surge during this period can be credited to the development of AI and machine learning in the field of biomarker study, the escalating demand for early detection of disease, the expansion of telemedicine and remote medical diagnostics, an increased incidence of chronic diseases, and heightened health consciousness among consumers. Noteworthy advancements in this period are predicted to include AI-engineered biomarker discovery, development in liquid biopsy, multi-omics integration, point-of-care (POC) testing tools, and innovative strides in next-generation sequencing (NGS).

View the full report here:
https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report

Top Growth Drivers in the Blood Based Biomarkers Industry: What's Accelerating the Market?
The escalating instances of cardiovascular diseases are predicted to fuel the expansion of the market for blood-based biomarkers. These diseases include disorders impacting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. Factors like unhealthy diet and growing obesity rates contribute mainly to the uptick in these conditions. Blood-based biomarkers play a crucial part in diagnosing and monitoring cardiovascular diseases, offering valuable data concerning disease progression, risk evaluation, and treatment efficacy through traceable substances found in blood. For example, in September 2024, based on the National Center for Biotechnology Information, a government agency in the US unveiled a worldwide health investigation. Forecasts showed a surge of 90% in the prevalence of cardiovascular disease from 2025 to 2050, anticipating cardiovascular-related deaths to hit 35.6 million by 2050. Consequently, the rising instances of cardiovascular diseases are fuelling the expansion of the blood-based biomarkers market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

What Are the Key Trends Driving Blood Based Biomarkers Market Growth?
Leading enterprises in the blood-based biomarkers market are prioritizing technological progress such as high-precision blood biomarker tests to assist physicians in diagnosing Alzheimer's disease. High-accuracy blood biomarker tests are diagnostic tools that identify diseases or monitor health conditions using unique biomarkers in the blood with exceptional precision and dependability. For instance, in October 2023, Quanterix, a bio-science firm based in the US, unveiled the LucentAD p-Tau 217, a highly precise blood biomarker test designed to help physicians diagnose Alzheimer's disease (AD) in adults exhibiting cognitive dysfunction. The test evaluates the phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker closely linked to AD pathology, particularly with amyloid accumulation in the brain. Boasting over 90% accuracy, the LucentAD p-Tau 217 meets rigorous diagnostic standards and is purposed to complement other diagnostic instruments rather than serve as an independent test.

What Are the Main Segments in the Blood Based Biomarkers Market?
The blood based biomarkers market covered in this report is segmented -

1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies
3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications
4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users

Subsegments:

1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions
2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins
3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels
4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells
5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24176&type=smp

Which Top Companies are Driving Growth in the Blood Based Biomarkers Market?
Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG

Which Regions Will Dominate the Blood Based Biomarkers Market Through 2029?
North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24176

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay,
Americas: +1 310-496-7795,
Asia: +44 7882 955267 & +91 8897263534,
Europe: +44 7882 955267,
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.